Artificial intelligence is beginning to transform patent practice, but for chemistry and biotech, the challenges remain unique.

How well do today’s AI tools truly understand complex scientific inventions? What can they already help patent practitioners within the life sciences area? Where do AI tools still fall short for chemistry and biotech? How do experts in the field see AI tools evolving to address chemistry and biotech inventions?

Join us on Thursday, November 18, at 12 PM ET, for an IPWatchdog conversation. Moderated by Gene Quinn, founder of IPWatchdog, leading experts from the life sciences industry, private practice, and AI innovation will discuss the current state of AI adoption in chemistry and biotech patent work. Our panel will include Carola Lempke, Director of Patents at AstraZeneca; Monique Perdok, Principal at Schwegman, Lundberg & Woessner; Sean Patrick Suiter, Patent Attorney and Founder of Suiter Swantz IP; and Edouard d’Archimbaud, CTO & Co-Founder of DeepIP.

Together, the panel will explore:

• What tasks AI can realistically support today.
• The scientific and linguistic hurdles unique to chemical and biological inventions.
• The progress AI tools have made on life sciences and pitfalls to avoid.
• Balancing efficiency, accuracy, and confidentiality when experimenting with AI.
• What is next on the horizon for AI-assisted patent practice in life sciences.

The conversation will conclude with a short demo of the DeepIP platform, showing how AI can assist patent professionals in high-complexity fields – such as chemistry and biotech – while maintaining quality and security standards.